+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Anti-obesity Medication Market Size, Share & Trends Analysis Report by Product (Approved, Off-label), Mechanism Of Action (Peripherally Acting Drugs, Centrally Acting Drugs), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 110 Pages
  • March 2024
  • Region: Global
  • Grand View Research
  • ID: 5950087
Description Jump to:
The global anti-obesity medication market size is expected to reach USD 77.24 billion by 2030. The market is expected to grow at a CAGR of 31.66% from 2024 to 2030. The market is experiencing significant growth driven by the increasing prevalence of obesity, leading to increased demand for effective treatments. The market's expansion is supported by technological advancements and initiatives by both market players and governments.

The market players are actively pursuing strategic initiatives to expand their service reach through partnerships, mergers, acquisitions, and collaborations. These initiatives are aimed at driving market share growth. For instance, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling over USD 2.32 billion, will boost capacity for chronic disease treatments, potentially including weight management medications. In addition, governments and healthcare organizations prioritize obesity prevention and treatment, collaborative efforts are shaping regulatory frameworks and fostering innovation. This highlights the market's collective effort. For instance, in June 2023, the UK launched a USD 50.50 million pilot to broaden access to overweight drugs such as Semaglutide (Wegovy) beyond hospital environments, aligning with the government's comprehensive approach to addressing overweight.

Moreover, social media influence and forged prescriptions indicate non-diabetic usage for weight loss, prompting ANSM (Agence nationale de sécurité du médicament et des produits de santé) to emphasize Ozempic's intended use solely for diabetes treatment. However, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling overUSD 2.32 billion, will boost capacity for chronic disease treatments, potentially including anti-obesity medications. Despite regulatory challenges, such investments indicate optimism for the future of the anti-obesity medication market in France, suggesting a positive trajectory in the projected period.

The rising obesity has a direct impact on the expansion of the obesity treatment industry, providing new business opportunities for pharmaceutical firms, healthcare services, and related parties. With the costs linked to managing obesity increasing, there is a pressing need for creative strategies and measures to combat this health crisis and achieve sustainable cost control within the healthcare sector.

Anti-obesity Medication Market Report Highlights

  • By products, the approved segment accounted for the largest market share in 2023. It is expected to grow at a lucrative CAGR over the forecast period, owing to the accessibility of therapeutically effective weight management drugs
  • Based on mechanism of action, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share in 2023. The ability of these drugs to enhance the absorption of nutrients and reduce the feeling of hunger is anticipated to bode well for the segment’s growth.
  • Retail pharmacies dominated the distribution channel segment in 2023, owing to the convenient access to medications for consumers, often located in easily accessible locations within communities
  • North America dominated the market for anti-obesity medication in 2023, due to the region's high prevalence of obesity and supportive government policies
  • Asia Pacific is anticipated to exhibit the fastest CAGR from 2024 to 2030, due to rising obesity and governmental initiatives across countries like China, Japan, and India. The rising investment in research by pharmaceutical companies is also expected to contribute to this growth.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Mechanism of Action
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Mechanism of Action outlook
2.2.3. Distribution Channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Anti-Obesity Medication Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Prevalence of Obesity-Related Conditions
3.2.1.2. Government Regulations and Guidelines
3.2.1.3. Increase in technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Side Effects and Adverse Reactions
3.2.2.2. High cost of anti-obesity drugs
3.3. Anti-Obesity Medication Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Anti-Obesity Medication Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Anti-Obesity Medication Market by Product Outlook
4.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Approved
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1. Bupropion-naltrexone (Contrave)
4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Liraglutide (Saxenda)
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Orlistat
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3.2. Xenical
4.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3.3. Alli
4.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Phentermine-topiramate (Qsymia)
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Semaglutide (Wegovy)
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.6. Setmelanotide (Imcivree)
4.4.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.7. Tirzepatide (Zepbound)
4.4.1.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Off Label
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.1. Semaglutide (Ozempic)
4.4.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.2. Liraglutide (Victoza)
4.4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.3. Dulaglutide (Trulicity)
4.4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.4. Topiramate (Dulaglutide (Trulicity))
4.4.2.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.1.5. Other
4.4.2.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Anti-Obesity Medication Market: Mechanism of Action Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Anti-Obesity Medication Market Movement Analysis
5.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
5.4. Peripherally Acting Drugs
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Centrally Acting Drugs
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Anti-Obesity Medication Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Anti-Obesity Medication Market Movement Analysis
6.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Hospital Pharmacies
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Anti-Obesity Medication Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Mexico
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. Argentina
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Novo Nordisk A/S
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. GSK plc
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Novartis AG
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. VIVUS LLC
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Currax Pharmaceuticals LLC
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Boehringer Ingelheim International GmbH
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Rhythm Pharmaceuticals, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Gelesis
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
List of Tables
Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies’/technology disruptors/innovators
Table 3 North America Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 4 North America Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 5 North America Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 6 North America Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 7 U.S. Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 8 U.S. Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 9 U.S. Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 10 Canada Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 11 Canada Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 12 Canada Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 13 Europe Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 14 Europe Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 15 Europe Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 16 Europe Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 18 Germany Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 19 Germany Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 UK Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 21 UK Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 22 UK Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 France Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 24 France Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 25 France Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Italy Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 27 Italy Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 28 Italy Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Spain Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 30 Spain Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 31 Spain Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Denmark Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 33 Denmark Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 34 Denmark Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 Sweden Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 36 Sweden Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 37 Sweden Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Norway Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 39 Norway Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 40 Norway Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Japan Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 46 Japan Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 47 Japan Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 48 China Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 49 China Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 50 China Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 51 India Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 52 India Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 53 India Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 54 Australia Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 55 Australia Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 56 Australia Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 57 South Korea Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 58 South Korea Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 59 South Korea Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 60 Thailand Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 61 Thailand Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 62 Thailand Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 63 Latin America Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 64 Latin America Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 65 Latin America Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 66 Latin America Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Brazil Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 68 Brazil Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 69 Brazil Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 70 Mexico Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 71 Mexico Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 72 Mexico Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 73 Argentina Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 74 Argentina Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 75 Argentina Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 76 MEA Anti-Obesity Medication Market, by country, 2018 - 2030 (USD Million)
Table 77 MEA Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 78 MEA Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 79 MEA Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 80 South Africa Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 81 South Africa Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 82 South Africa Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 86 UAE Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 87 UAE Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 88 UAE Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 89 Kuwait Anti-Obesity Medication Market, by Product, 2018 - 2030 (USD Million)
Table 90 Kuwait Anti-Obesity Medication Market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 91 Kuwait Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Anti-Obesity Medication Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain - based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Anti-Obesity Medication Market snapshot (2023)
Fig. 9 Anti-Obesity Medication Market: Segment snapshot (2023)
Fig. 10 Competitive Insights (2023)
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Anti-Obesity Medication Market driver impact
Fig. 15 Anti-Obesity Medication Market restraint impact
Fig. 16 Clinical chemistry industry challenges
Fig. 17 Porter’s Five Forces Analysis
Fig. 18 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 19 Strategic alliance analysis
Fig. 20 Recent developments & impact analysis, by key market participants
Fig. 21 Key company market share analysis, 2023
Fig. 22 Company market position analysis
Fig. 23 Definition and scope, by product
Fig. 24 Product market share analysis, 2023 & 2030
Fig. 25 Segment dashboard
Fig. 26 Global Anti-Obesity Medication Market, by product, 2018 - 2030 (USD Million)
Fig. 27 Approved market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 28 Bupropion - naltrexone (Contrave) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 29 Liraglutide (Orlistat) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 30 Orlistat market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 31 Xenical market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 32 Alli market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 33 Phentermine - topiramate (Qsymia) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 34 Semaglutide (Wegovy) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 35 Tirzepatide (Zepbound) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 36 Setmelanotide (Imcivree) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 37 Off Label market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 38 Semaglutide (Ozempic) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 39 Liraglutide (Victoza) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 40 Dulaglutide (Trulicity) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 41 Topiramate (Dulaglutide (Trulicity)) market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 42 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 43 Definition and scope, by Distribution Channel
Fig. 44 Distribution Channel market share analysis, 2023 & 2030
Fig. 45 Segment dashboard
Fig. 46 Global Anti-Obesity Medication Market, by Distribution Channel, 2018 - 2030 (USD Million)
Fig. 47 Retail Pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 48 Hospital Pharmacies market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 49 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 50 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 51 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 52 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 53 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 54 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 55 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 56 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 57 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 58 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 59 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 60 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 61 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 62 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 63 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 64 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 65 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 66 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 67 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 68 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 69 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 70 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 71 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 72 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
Fig. 73 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 74 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 75 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 76 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 77 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)

Companies Mentioned

  • Novo Nordisk A/S
  • GSK plc
  • Novartis AG
  • VIVUS LLC
  • Currax Pharmaceuticals LLC
  • Boehringer Ingelheim International GmbH
  • Rhythm Pharmaceuticals, Inc.
  • Gelesis

Methodology

Loading
LOADING...

Related Topics

Related Reports

Global Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Forecast 2024-2030 - Product Image

Global Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From
Global Anti-obesity Prescription Drugs Market by Drug Class (Bupropion & Naltrexone, Liraglutide, Lorcaserin), Age Group (Adult, Pediatric), Distribution Channel - Forecast 2024-2030 - Product Image

Global Anti-obesity Prescription Drugs Market by Drug Class (Bupropion & Naltrexone, Liraglutide, Lorcaserin), Age Group (Adult, Pediatric), Distribution Channel - Forecast 2024-2030

  • Report
  • 189 Pages
  • Global
From
Growth Opportunities in Obesity Drugs and Delivery Platforms - Product Image

Growth Opportunities in Obesity Drugs and Delivery Platforms

  • Report
  • 51 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.